CMS: Next Day Disclosure Return
Apr 24 18:50
CMS: Voluntary and Business Update Announcement New Drug Application of Desidustat Tablets Accepted in China
Apr 23 20:04
CMS: Next Day Disclosure Return
Apr 17 19:32
CMS: NOTIFICATION LETTER
Apr 17 17:18
CMS: FORM OF PROXY
Apr 17 17:10
CMS: Environmental, Social and Governance Report 2023
Apr 17 16:50
CMS: Voluntary and Business Update Announcement New Drug Application of Ruxolitinib Cream Approved in Macau
Apr 16 22:34
CMS: Next Day Disclosure Return
Apr 15 19:56
CMS: Next Day Disclosure Return
Apr 12 19:28
CMS: Next Day Disclosure Return
Apr 11 19:52
CMS: Next Day Disclosure Return
Apr 10 19:04
CMS: Next Day Disclosure Return
Apr 9 18:34
CMS: Next Day Disclosure Return
Apr 8 19:35
CMS: Next Day Disclosure Return
Apr 3 19:26
CMS: Next Day Disclosure Return
Apr 2 19:52
CMS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 2 17:33
CMS: Voluntary and Business Update Announcement Gaining Exclusive License for Oral Small-molecule JAK1 Inhibitor Povorcitinib for the Treatment of Vitiligo and Hidradenitis Suppurativa and Other Indications
Apr 1 18:22
CMS: VOLUNTARY ANNOUNCEMENT ADOPTION OF SHARE AWARD SCHEMES RELATED TO CMS NEW PRODUCTS
Mar 27 22:51
CMS: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023
Mar 27 22:47
CMS: Voluntary and Business Update Announcement Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China
Mar 19 20:17
No Data
No Data